Compare Abeona Therapeutics Inc (ABEO) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MGM Resorts International — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while MGM Resorts International trades at $46.64 (market cap $11.93B). The key difference: MGM Resorts International is far larger — about 32× Abeona Therapeutics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MGM | |
|---|---|---|
Market Cap | $373.32M | $11.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $50.69 |
52-Week Low | $4.17 | $30.72 |
Enterprise Value | $228.22M | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MGM Resorts International (MGM) trades at $46.64, down 0.98% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.49, slightly missing expectations, while Q4 2025 saw a significant beat. Revenue growth has been steady, reaching $17.54B in 2025, though net income margins have compressed to 1.03%. Recent news highlights a potential acquisition offer from Barry Diller at $48.30 per share, under investigation by BFA Law.
The outlook for MGM is cautiously optimistic, supported by analyst consensus leaning Buy (48.64%) and a price target of $45.45. Opportunities include strategic partnerships and digital expansion via BetMGM, but risks persist from high debt levels, regulatory scrutiny, and volatile earnings performance. Investors should weigh the acquisition premium against fundamental valuation metrics like a high P/E of 64.22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
